Table 3.
Summary of discontinuations and adverse events (AEs)
| Characteristic | N = 73 |
|---|---|
| Discontinued (overall) | 8 (11) |
| AE | 3 (4) |
| Withdrawn consent | 3 (4) |
| Disease progression | 1 (1) |
| Death | 1 (1) |
| AEs (any event) | 71 (97) |
| Cough | 54 (74) |
| Headache | 32 (44) |
| Nausea | 22 (30) |
| Chest discomfort | 12 (16) |
| Flushing | 11 (15) |
| Nasopharyngitis | 11 (15) |
| Upper respiratory tract infection | 11 (15) |
| Dizziness | 10 (14) |
| Palpitations | 9 (12) |
| Throat irritation | 9 (12) |
| Fatigue | 8 (11) |
| Oropharyngeal pain | 7 (10) |
| Productive cough | 7 (10) |
Values are n (%). Includes AEs occurring in at least 10% of patients. Mean exposure 32.4 weeks (range: 0.4–56.0).